IBI-346

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameIBI-346
Drug Alias NameIBI-346
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein modulators
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A